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Introduction {#sec1}
============

Under normal conditions the liver is an organ with slow parenchymal cell turnover, and the lifespan of hepatocytes can reach 200--300 days in a resting state. During homeostasis, it is generally believed that the liver lacks a multipotent stem cell population to maintain organ renewal, and thus ductal cells and hepatocytes are unipotent ([@bib19]). Previous studies have indicated that facultative stem cells, also known as atypical ductal cells or oval cells, can differentiate into hepatocytes ([@bib7], [@bib21]). Studies using Hnf1b or osteopontin (OPN) promoter-driven Cre fate mapping have suggested that liver progenitor cells or biliary epithelial cells could give rise to hepatocytes after liver injuries ([@bib5], [@bib25]). However, recent lineage-tracing studies reported that virtually all hepatocytes are derived from pre-existing hepatocytes before injury rather than differentiating from stem cells ([@bib10], [@bib18], [@bib27], [@bib35], [@bib36]). Following severe chronic liver injury in which the proliferative potential of hepatocytes is significantly inhibited, a group of hepatic progenitor cells (HPCs) contribute significantly to the restoration of liver parenchyma, generating both hepatocytes and biliary epithelia ([@bib16]). Indeed, following severe and chronic liver injuries that impair hepatocyte proliferation, committed ductal cells or cholangiocytes can act as facultative liver stem cells and generate hepatocytes for liver repair and regeneration ([@bib4], [@bib24]). Conversely, hepatocytes can undergo hepatocyte-to-ductal cell transition after certain injuries ([@bib37]). In an animal model of human Alagille syndrome, hepatocytes could also convert into *de novo* mature biliary epithelial cells that form functional bile ducts ([@bib26]). Under chronic injury, mature hepatocytes could generate bipotential adult liver progenitors that give rise to both ductal cells and hepatocytes ([@bib32]). These studies indicated that mature hepatocytes or ductal cells could be reprogrammed into counterparts under certain conditions, as demonstrated in extremely severe liver injury models that promote cell-lineage conversion and cell plasticity. While these studies involved genetic lineage tracing at the population level, it remains unclear whether a single cell such as a hepatocyte is predetermined to give rise to hepatocytes, biliary epithelial cells, or both during injury. Unraveling the potency and plasticity of committed hepatocytes may provide evidence to help elucidate the liver progenitor cell hierarchy and their roles in liver repair and regeneration.

*Sox9* (sry-related high mobility group-box gene 9) is a family gene homolog located on the male Y chromosome ([@bib30]). In the liver, SOX9 regulates the development of intrahepatic bile ducts through a mode of tubulogenesis ([@bib1]). [@bib9] reported that SOX9^+^ ductal epithelial cells are endogenous HPCs that contribute to hepatocytes during liver homeostasis and after injuries. Subsequent lineage-tracing studies using a multicolored fluorescent Confetti reporter showed that SOX9^+^ cells contribute only minimally (\<1%) to hepatocytes ([@bib31]). Because SOX9 is also expressed in a subset of hepatocytes, albeit at a lower level compared with that in ductal cells ([@bib8], [@bib37]), the rare contribution of SOX9^+^ cells to hepatocytes could be due to prelabeled hepatocytes that express SOX9 ([@bib14]). Indeed, these SOX9^+^ hepatocytes undergo extensive proliferation and replenish liver mass after chronic liver injuries without giving rise to hepatocellular carcinoma ([@bib8]), indicating that SOX9^+^ hepatocytes could be an important source of hepatocytes with therapeutic potential. It remains unknown whether individual SOX9^+^ hepatocytes are unipotent (ductal cell or hepatocyte lineage) or bipotent (both ductal cell and hepatocyte lineages) during liver injury and repair.

The genetic lineage-tracing technique is an effective method for unraveling cell fate in development, disease, and regeneration ([@bib34]). The conventional genetic tracing method depends on a singular gene marker that may show low efficacy in defining one particular cell population. For example, *Sox9-CreER* targets both periportal hepatocytes and biliary epithelial cells. To achieve more precise labeling of cell lineages and trace their cell fate *in vivo*, we recently incorporated a recombination system, Dre-rox, to supplement Cre-loxP for enhancing the precision of genetic lineage tracing ([@bib14]). In this study, we generated an intersectional genetic strategy showing that a subset of SOX9^+^ hepatocytes, at the single-cell level, are bipotent progenitors that differentiate into both hepatocytes and biliary epithelial cells during liver injury and repair.

Results {#sec2}
=======

Characterization of *Sox9-CreER* and *Hnf4a-DreER* Mouse Lines {#sec2.1}
--------------------------------------------------------------

SOX9^+^ hepatocytes express both SOX9 and hepatocyte markers, such as HNF4a, but do not express the biliary epithelial cell marker CK19 ([@bib14]). For lineage tracing of SOX9^+^HNF4a^+^ hepatocytes, we generated two distinct mouse lines that utilize two orthogonal recombinases: *Sox9-CreER* and *Hnf4a-DreER*. The *Sox9-CreER* mouse was crossed with the *R26-RFP* reporter mouse to generate the *Sox9-CreER*;*R26-RFP* mouse. Tamoxifen induction led to Cre-loxP recombination, which resulted in permanent labeling of SOX9^+^ cells and all their descendants ([Figure 1](#fig1){ref-type="fig"}A). Whole-mount fluorescence imaging of *Sox9-CreER*;*R26-RFP* livers showed that a substantial number of hepatic cells were labeled after tamoxifen induction ([Figure 1](#fig1){ref-type="fig"}B). Immunostaining for RFP, the hepatocyte marker HNF4a, or the ductal cell marker CK19 on *Sox9-CreER*;*R26-RFP* liver sections showed that RFP^+^ cells were HNF4a^+^ or CK19^+^ ([Figures 1](#fig1){ref-type="fig"}C and 1D), indicating hepatocytes and ductal cells/biliary epithelial cells (BECs), respectively. Notably, most RFP^+^ hepatocytes were close to the portal vein region where BECs were located, which is consistent with previous reports. Staining of the periportal hepatic zonation marker E-cadherin (E-CAD) verified that these SOX9^+^ hepatocytes were periportal hepatocytes ([Figure 1](#fig1){ref-type="fig"}E). Quantification of hepatocyte labeling efficiency showed that 96.51% ± 0.38% of BECs were RFP^+^ and 5.49% ± 1.93% of hepatocytes were RFP^+^ ([Figure 1](#fig1){ref-type="fig"}F). Of these positive hepatocytes, almost all were positive for E-CAD (\>99%, [Figure 1](#fig1){ref-type="fig"}F), suggesting periportal hepatocytes. To confirm that SOX9 protein was indeed expressed in the hepatocytes in addition to BECs, we also collected the tissues 24 h after tamoxifen induction and stained them for RFP, SOX9, and E-CAD. We found that SOX9 was expressed in a subset of periportal hepatocytes (arrows) as well as BECs (arrowheads, [Figure 1](#fig1){ref-type="fig"}G).Figure 1Fate Mapping of Hepatic Cell Lineages by *Sox9-CreER* or *Hnf4a-DreER*(A and H) Schematic figure showing lineage-tracing strategy by *Sox9-CreER*;*R26-RFP* (A) or *Hnf4a-DreER*;*R26-RSR-RFP* (H).(B and I) Whole-mount fluorescence views of livers from 8-week-old adult mice. Tamoxifen was induced 4 days later. Insets indicate bright-field images.(C and J) Immunostaining for RFP and HNF4a on liver sections.(D and K) Immunostaining for RFP and CK19 on liver sections.(E) Immunostaining for RFP and periportal hepatocyte marker E-CAD on liver sections.(F) Quantification of the percentage of labeled CK19^+^ biliary epithelial cells (BECs) or HNF4a^+^ hepatocytes (left panel). The percentage of E-CAD^+^ or E-CAD^-^ cells in labeled hepatocytes is shown on the right panel. Data are mean ± SEM; n = 5.(G) Immunostaining for SOX9, RFP, and periportal hepatocyte marker E-CAD on liver sections.(L) Quantification of the percentage of labeled cells among different lineages. Data are mean ± SEM, n = 5.(M) Cartoon image showing the fate mapping of hepatic cells by *Sox9-CreER* or *Hnf4a-DreER*. Scale bars, 1 mm (B and I) and 100 μm (C--E, G, J, and K).

We next generated an *Hnf4a-DreER* knockin mouse by placing the DreER cDNA in-frame with the initiating ATG of the *Hnf4a* gene ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The *Hnf4a-DreER* mouse was crossed with the *R26-rox-stop-rox-RFP* (*R26-RSR-RFP*) reporter to generate the *Hnf4a-DreER*;*R26-RSR-RFP* mouse. Tamoxifen treatment induced Dre-rox recombination, which removed the Stop cassette and led to RFP expression in HNF4a^+^ hepatocytes ([Figure 1](#fig1){ref-type="fig"}H). Whole-mount fluorescence imaging of *Hnf4a-DreER*;*R26-RSR-RFP* mouse liver showed RFP^+^ signals throughout the entire liver ([Figure 1](#fig1){ref-type="fig"}I). Immunostaining for RFP, HNF4a, CK19, or EpCAM on liver sections showed that HNF4a^+^ hepatocytes were RFP^+^, while CK19^+^ or EpCAM^+^ BECs were RFP^--^ ([Figures 1](#fig1){ref-type="fig"}J, 1K, and [S1](#mmc1){ref-type="supplementary-material"}B). We also stained other cell-lineage markers, such as desmin, α-smooth muscle actin (αSMA), VE-cadherin, platelet-derived growth factor receptor α (PDGFRα), and E-CAD, with RFP on liver sections and found that RFP^+^ cells were parenchymal epithelial cells but not endothelial cells, smooth muscle cells, hepatic satellite cells, or fibroblasts ([Figures S1](#mmc1){ref-type="supplementary-material"}C--S1G). Quantification of labeled cells showed that 80.25% ± 2.03% of hepatocytes were RFP^+^ while other cell lineages did not express RFP in *Hnf4a-DreER*;*R26-RSR-RFP* ([Figure 1](#fig1){ref-type="fig"}L). Taken together, these data demonstrated that *Hnf4a-DreER* specifically and efficiently targeted hepatocytes in the liver. While *Sox9-CreER* labeled BECs and a subset of periportal hepatocytes, *Hnf4a-DreER* labeled only hepatocytes ([Figure 1](#fig1){ref-type="fig"}M); thus, SOX9^+^HNF4a^+^ hepatocytes could then be targeted by *Sox9-CreER* and *Hnf4a-DreER* dual recombinases.

Specific Labeling of SOX9^+^ Hepatocytes by Dual Recombinases {#sec2.2}
-------------------------------------------------------------

To achieve specific labeling of SOX9^+^ hepatocytes, we needed to target SOX9^+^ HNF4a^+^ cells in the liver by intersectional genetics ([Figure 2](#fig2){ref-type="fig"}A) so that the double-positive cell population could be distinguished from single positive cells. We crossed the characterized *Hnf4a-DreER* and *Sox9-CreER* mice with a dual recombinase-mediated RFP reporter (*R26-rox-Stop-rox-loxp-Stop-loxp-RFP*, as *R26-Ai66*) to generate the *Sox9-CreER*;*Hnf4a-DreER*;*R26-Ai66* triple-positive mouse line ([Figure 2](#fig2){ref-type="fig"}B). In this reporter line, activation of RFP required both Dre-rox and Cre-loxP recombination, which removed transcriptional Stop cassettes. Therefore, only SOX9^+^HNF4a^+^ hepatocytes that harbored both Cre and Dre recombinases could be genetically labeled ([Figure 2](#fig2){ref-type="fig"}B). With this genetic design, single positive cell populations, such as SOX9^+^HNF4a^--^ cells (BECs) or SOX9^--^HNF4a^+^ hepatocytes, remained unlabeled ([Figure 2](#fig2){ref-type="fig"}B). One week after tamoxifen induction, livers were collected from *Sox9-CreER*;*Hnf4a-DreER*;*R26-Ai66* mice for analysis. Immunostaining of liver sections for CK19 and HNF4a showed labeling of hepatocytes in the periportal zone of the liver lobule, and BECs were RFP^--^ ([Figure 2](#fig2){ref-type="fig"}C), demonstrating selective labeling of SOX9^+^HNF4a^+^ hepatocytes. We examined the littermate controls *Sox9-CreER*;*R26-Ai66* or *Hnf4a-DreER*;*R26-Ai66* and performed the same tamoxifen induction strategy and immunostaining for subsequent analysis. In both groups, no RFP^+^ hepatocytes or BECs were detected ([Figures 2](#fig2){ref-type="fig"}D and 2E), demonstrating that RFP expression required both Cre-loxP and Dre-rox recombination. Taken together, these data demonstrated the successful generation of a mouse genetic tool for targeting SOX9^+^ hepatocytes in the liver.Figure 2Lineage Tracing of SOX9^+^ Hepatocytes by Dural Recombination(A) Schematic showing intersectional genetics for labeling of double-positive cells (SOX9^+^Hnf4a^+^).(B) Schematic showing lineage-tracing strategy by Dre-rox and Cre-loxP recombinations. Dural recombination, but not singular one, labels SOX9^+^Hnf4a^+^ hepatocytes.(C--E) Immunostaining for RFP, CK19, and HNF4a on liver sections shows periportal RFP^+^HNF4a^+^ hepatocytes (arrowheads) in *Sox9-CreER*;*Hnf4a-DreER*;*R26-Ai66* (C) but not in *Sox9-CreER*;*R26-Ai66* (D) or *Hnf4a-DreER*;*R26-Ai66* (E) liver sections. Cartoon images on right panels show labeling result. Each figure is representative of five individual samples. Scale bars, 100 μm.

SOX9^+^ Hepatocytes Expand Significantly after CCl~4~-Induced Liver Injury {#sec2.3}
--------------------------------------------------------------------------

To examine the cell dynamics of SOX9^+^ hepatocytes after liver injuries, we injected *Sox9-CreER*;*Hnf4a-DreER*;*R26-Ai66* mice with CCl~4~ or performed a partial hepatectomy (PHx) to induce liver injuries. CCl~4~ injury induces injury in the pericentral regions and stimulates the expansion of compensatory growth of periportal hepatocytes ([@bib23]), while PHx induces more general hepatocyte growth throughout the liver, including hepatocyte hypertrophy and compensatory hepatocyte proliferation ([@bib19]). Tamoxifen was induced at 8 weeks old, and after a 2-week washout period, mice were treated 10 times with CCl~4~ and liver samples collected at 14 weeks (after injury) and 18 weeks (recovery group) for analysis ([Figure 3](#fig3){ref-type="fig"}A). Sirius red staining of liver sections showed strong fibrosis in the injured liver compared with that of the oil-treated control group, and tissue fibrosis was reduced in the recovery group 4 weeks after the last CCl~4~ treatment ([Figure 3](#fig3){ref-type="fig"}B). Whole-mount fluorescent imaging of livers showed significant RFP signals in the injury and recovery group compared with the control group ([Figure 3](#fig3){ref-type="fig"}C). Immunostaining for CK19 and RFP showed that these RFP^+^ cells did not contribute to CK19^+^ BECs and remained as hepatocytes in the injured and recovered livers ([Figure 3](#fig3){ref-type="fig"}D). We also stained E-CAD in tissue sections of the control, CCl~4~ injury, and recovery groups. We found that RFP^+^ hepatocytes remained in zone 1 (E-CAD^+^) before injury. During CCl~4~ injury, the zone-1 marker E-CAD was expressed throughout the liver. After recovery the zonation was restored, with E-CAD expression restricted mainly to the periportal hepatocytes. Interestingly, a subset of the expanded RFP^+^ hepatocytes extended to the pericentral regions and no longer maintained E-CAD expression, indicating reprogramming of SOX9-derived hepatocytes after CCl~4~-induced liver injury ([Figure 3](#fig3){ref-type="fig"}D). Quantitatively, the percentage of RFP^+^ hepatocytes was significantly higher in the injured liver and recovered liver than in the control group (15.22% ± 1.57%, 12.99% ± 1.51%, and 2.55% ± 0.28%, respectively, [Figure 3](#fig3){ref-type="fig"}E), indicating expansion of SOX9^+^ hepatocytes in CCl~4~-induced injury ([Figure 3](#fig3){ref-type="fig"}F).Figure 3SOX9^+^ Hepatocytes Contribute Parenchymal Restoration after CCl~4~-Induced Liver Damage(A) Experimental strategy for tamoxifen treatment (Tam) and tissue analysis at different time points after injury.(B) Sirius red staining of liver sections from oil (Control) or CCl~4~-treated mice.(C) Whole-mount fluorescence view of *Sox9-CreER*;*Hnf4a-DreER*;*Rosa26-Ai66* liver after oil (Control) or CCl~4~ treatment or recovery.(D) Immunostaining for RFP, CK19, and E-CAD on liver sections shows the expansion of RFP^+^ hepatocytes following injuries.(E) Quantification of RFP^+^ hepatocytes in control, injury, or recovery groups. Data are mean ± SEM, n = 5; ^∗^p \< 0.05.(F) Cartoon image showing expansion of SOX9^+^ hepatocytes after injury.Scale bars, 200 μm (B), 1 mm (C, left), 500 μm (C, right), and 100 μm (D).

We also performed PHx in 10-week-old mice and analyzed liver tissues at 12--14 weeks of age ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Sirius red staining showed that there was no significant tissue fibrosis in the sham or recovery group 2 weeks or 4 weeks after the operation (R2W or R4W, [Figure S2](#mmc1){ref-type="supplementary-material"}B). By whole-mount fluorescent imaging and sectional immunostaining for RFP, we found that SOX9^+^ hepatocytes did not expand preferentially after PHx compared with SOX9^--^ hepatocytes ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E). By immunostaining with the BEC marker CK19, we found that these SOX9^+^ hepatocytes did not give rise to BECs after PHx and remained as hepatocytes after injury ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We observed an increase in Ki67^+^ hepatocytes after PHx injury compared with the sham control ([Figure S2](#mmc1){ref-type="supplementary-material"}F). However, the percentage of RFP^+^ hepatocytes did not change significantly, indicating that PHx did not preferentially induce SOX9^+^ hepatocyte expansion. Thus, SOX9^+^ hepatocytes are a unique cell population that responds to a certain type of liver injury (such as CCl~4~) through significant self-expansion.

SOX9^+^ Hepatocytes Contribute to Cholangiocytes after Bile Duct Ligation or DDC-Induced Liver Injury {#sec2.4}
-----------------------------------------------------------------------------------------------------

Previous work reported that bile duct ligation (BDL) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) treatment induces hepatocytes to transition into BECs ([@bib20], [@bib32]). We next examined whether SOX9^+^ hepatocytes contribute to BECs after BDL- or DDC-induced liver injury. After tamoxifen treatment and a 2-week washout period, *Sox9-CreER*;*Hnf4a-DreER*;*R26-Ai66* mice were subjected to BDL at 10 weeks old, and livers were collected at 12 or 14 weeks for analysis ([Figure 4](#fig4){ref-type="fig"}A). BDL resulted in significant liver fibrosis compared with the sham group ([Figure 4](#fig4){ref-type="fig"}B). In contrast to the CCl~4~ treatment, BDL injury did not stimulate significant expansion of SOX9^+^ hepatocytes ([Figure 4](#fig4){ref-type="fig"}C). Notably, a subset of RFP^+^ hepatocytes gave rise to BECs in the BDL-injured liver, while RFP^+^ BECs were not detected in the sham control group ([Figure 4](#fig4){ref-type="fig"}C). Quantitatively, 2.48% ± 0.19% and 0.99% ± 0.28% of hepatocytes were RFP^+^ in the sham and injury groups, respectively (^∗^p \< 0.05; n = 5) ([Figure 4](#fig4){ref-type="fig"}D), indicating that BDL injury significantly reduced the SOX9^+^ hepatocyte population. The reduction in SOX9^+^ hepatocytes could be due to the lower competence of SOX9^+^ hepatocytes in expansion compared with SOX9^--^ hepatocytes during liver injury. It is also likely that SOX9^+^ hepatocytes have an enhanced potential to develop into BECs. In the BDL liver, 3.46% ± 0.33% of BECs were RFP^+^, indicating that SOX9^+^ hepatocytes differentiated into BECs after BDL injury ([Figures 4](#fig4){ref-type="fig"}E and 4F). Tamoxifen induction in *Alb-CreER*;*R26-RFP* mice resulted in labeling of almost all hepatocytes (\>99%, n = 5), and 10.49% ± 0.59% BECs were RFP^+^ in *Alb-CreER*;*R26-RFP* mouse livers after BDL injury ([Figures 4](#fig4){ref-type="fig"}G and 4H). In the liver, almost all hepatocytes contributed to approximately 10% of the BECs after BDL (99% hepatocytes to 10% BECs), while labeled SOX9^+^ hepatocytes that constituted less than 3% of all hepatocytes gave rise to over 3% of the BECs after BDL (∼3% hepatocytes to ∼3% BECs). Therefore, compared with the majority of hepatocytes that were negative for SOX9, this SOX9^+^ hepatocyte population had a greater propensity to differentiate into BECs after BDL.Figure 4SOX9^+^ Hepatocytes Contribute to Cholangiocytes after BDL- or DDC-Induced Liver Injury(A and I) Experimental strategies for tamoxifen treatment (Tam), liver injuries, and tissue analysis.(B and J) Sirius red staining of liver sections from control and BDL-treated (B) or DDC-treated (J) mice.(C and K) Immunostaining for RFP and CK19 on liver sections shows that SOX9^+^ hepatocytes contribute to BECs (arrowheads) following BDL-induced (C) or DDC-induced (K) liver injury.(D and L) Quantification of the RFP^+^ hepatocytes percentage. ^∗^p \< 0.05 (n = 5).(E and M) Quantification of RFP^+^ BECs percentage. ^∗^p \< 0.05 (n = 5).(F and N) Cartoon images showing contribution of SOX9^+^ hepatocyte to BEC (arrowheads) after BDL-induced (F) or DDC-induced (N) liver injury.(G and O) Immunostaining for RFP and CK19 on liver sections collected from *Alb-CreER*;*R26-RFP* after BDL-induced (G) or DDC-induced (O) injury.(H and P) Quantification of RFP^+^ BECs percentage. ^∗^p \< 0.05 (n = 5).Scale bars, 200 μm (B and J) and 50 μm (C, G, K, and O).

Alternatively, we also used a DDC-induced cholestatic liver injury model. Two weeks after tamoxifen treatment, mice were treated with DDC and liver samples were collected 8 weeks later ([Figure 4](#fig4){ref-type="fig"}I). Compared with the sham group, significant fibrosis was detected in the DDC-treated mouse livers ([Figure 4](#fig4){ref-type="fig"}J). Immunostaining for RFP and CK19 identified RFP^+^CK19^+^ BECs in the DDC-treated liver but not in controls ([Figure 4](#fig4){ref-type="fig"}K). Quantitatively, 2.59% ± 0.29% and 1.07% ± 0.14% of hepatocytes were RFP^+^ in the sham and DDC-treated livers, respectively (^∗^p \< 0.05; n = 5) ([Figure 4](#fig4){ref-type="fig"}L). In the DDC group, 3.63% ± 0.27% of BECs were RFP^+^, indicating the contribution of SOX9^+^ hepatocytes to BECs ([Figures 4](#fig4){ref-type="fig"}M and 4N). Likewise, we also induced *Alb-CreER*;*R26-RFP* mice with DDC and found that 11.31% ± 0.68% of BECs were RFP^+^ ([Figures 4](#fig4){ref-type="fig"}O and 4P). Quantitatively, \>99% of hepatocytes labeled by *Alb-CreER* contributed to ∼11% of BECs. In comparison, less than 3% of hepatocytes marked by SOX9 contributed to over 3% of BECs, indicating that SOX9^+^ hepatocytes might have a greater propensity to give rise to BECs after DDC-induced injury. Taken together, these data demonstrated that while the SOX9^+^ hepatocyte number was reduced, these cells contributed to *de novo* BECs after BDL or DDC injuries.

Generation of and Characterization of the *R26-Confetti2* Mouse Line {#sec2.5}
--------------------------------------------------------------------

The above data indicated that SOX9^+^ hepatocytes responded distinctly in different injury models. At the population level, SOX9^+^ cells could adopt both BEC and hepatocyte fates. We next asked whether some hepatocytes were predetermined to generate BECs or had the potential to generate both cell lineages during injury. To address this, we developed a strategy for single-cell clonal analysis of SOX9^+^HNF4a^+^ hepatocytes. The *R26-Confetti* reporter was previously generated to allow more precise clonal fate-mapping studies ([@bib29]). The conventional *R26-Confetti* is operated based on Cre-loxP recombination that leads to four different fluorescence readouts, permitting sparse labeling of cells in one color for more rigorous clonal analysis. To specifically label SOX9^+^HNF4a^+^ hepatocytes for clonal analysis, we generated a secondary version of *R26-Confetti* (*R26-Confetti2*) that was responsive to two orthogonal recombinases, Cre and Dre. A cDNA containing the CAG-rox-Stop-rox-Confetti cassette was knocked into the Rosa26 gene locus by homologous recombination ([Figure 5](#fig5){ref-type="fig"}A). When this *R26-Confetti2* reporter was crossed with Cre and Dre mouse lines, there were distinct fluorescent readouts for cells: Cre^+^Dre^--^ cells were negative for any fluorescence; Cre^--^Dre^+^ cells were positive for CFP but negative for other types of fluorescence; and Cre^+^Dre^+^ cells were positive for three fluorescent proteins, YFP, GFP, and RFP ([Figure 5](#fig5){ref-type="fig"}B). We next performed some control experiments to test whether *R26-Confetti2* worked as designed. For *R26-Confetti2* alone, there was no detectable fluorescence signal in the liver ([Figure 5](#fig5){ref-type="fig"}C). For *CAG-Dre*;*R26-Confetti2* mice, cells in the liver expressed CFP in whole-mount or sectional imaging ([Figure 5](#fig5){ref-type="fig"}D). CFP, but not other fluorescence signals, was also detected in other organs of *CAG-Dre*;*R26-Confetti2* mice ([Figure S3](#mmc1){ref-type="supplementary-material"}A). For *CAG-CreER*;*R26-Confetti2* mice treated with tamoxifen, there was no detectable fluorescence signal in the liver in whole-mount and sectional imaging ([Figure 5](#fig5){ref-type="fig"}E). We did not detect fluorescence signals in other organs or tissues ([Figure S3](#mmc1){ref-type="supplementary-material"}B). For *CAG-CreER*;*CAG-Dre*;*R26-Confetti2* mice treated with tamoxifen, we could detect CFP, GFP, YFP, and RFP signals in the liver ([Figure 5](#fig5){ref-type="fig"}F). Similarly, we detected these fluorescence signals in other organs, such as the heart ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Taken together, the above data indicated that *R26-Confetti2* functioned as expected and could be used for clonal analysis of single SOX9^+^HNF4a^+^ hepatocytes during liver injury.Figure 5Generation and Characterization of *R26-Confetti2* Mouse(A) Schematic showing strategy for generation of *R26-Confetti2* reporter allele by homologous recombination.(B) Distinct cell labeling after Cre and Dre recombinations.(C--E) Whole-mount fluorescent images of *R26-Confetti2* (C), *CAG-Dre*;*R26-Confetti2* (D), and *CAG-CreER*;*R26-Confetti2* (E) mouse livers. CFP is detected in *CAG-Dre*;*R26-Confetti2* liver and its section, but not in *R26-Confetti2* or *CAG-CreER*;*R26-Confetti2* livers. Tamoxifen was induced 2 days before tissue collection.(F) Fluorescent image of liver section from *CAG-CreER*;*CAG-Dre*;*R26-Confetti2* mouse. Tamoxifen was induced at 12.5 days before tissue collection.(G and H) Fluorescent images of liver sections from *Hnf4a-DreER*;*R26-Confetti2* (G) or *Sox9-CreER*;*R26-Confetti2* (H) mouse. There are no GFP, RF,P or YFP signals detected in liver sections.(I) Fluorescent image of *Hnf4a-DreER*;*Sox9-CreER*;*R26-Confetti2* mouse liver sections. Arrows indicate sparse RFP^+^ hepatocytes, and arrowheads indicate hepatocytes that have recombined with DreER but not CreER.Each image is representative of five individual samples. Scale bars, 100 μm.

We used *R26-Confetti2* for the analysis of SOX9^+^HNF4a^+^ hepatocytes during liver homeostasis. Mouse crossing generated three different genotypes among mouse littermates: *Hnf4a-DreER*;*R26-Confetti2*, *Sox9-CreER*;*R26-Confetti2*, and *Hnf4a-DreER*;*Sox9-CreER*;*R26-Confetti2*. For these three groups, we injected tamoxifen at the adult stage (8--10 weeks old) and then collected liver samples for analysis after 10--12 weeks. Sectional imaging of *Hnf4a-DreER*;*R26-Confetti2* liver tissues showed that hepatocytes were positive for CFP only ([Figure 5](#fig5){ref-type="fig"}G). There was no detectable fluorescence signal in *Sox9-CreER*;*R26-Confetti2* mouse livers ([Figure 5](#fig5){ref-type="fig"}H). In *Hnf4a-DreER*;*Sox9-CreER*;*R26-Confetti2* mice, Dre-rox recombination led to a subset of HNF4a^+^ hepatocytes labeled with CFP (arrowheads, [Figure 5](#fig5){ref-type="fig"}I). Both Dre-rox and Cre-loxP recombination led to one of the other three fluorescence signals, such as sparse RFP labeling in HNF4a^+^SOX9^+^ hepatocytes (arrow, [Figure 5](#fig5){ref-type="fig"}I). The sparsely labeled SOX9^+^ hepatocytes remained as single cells and did not contribute to any ductal cell during liver homeostasis.

Bipotency of Single SOX9^+^ Hepatocytes after Liver Injury {#sec2.6}
----------------------------------------------------------

After labeling sparse SOX9^+^ hepatocytes after tamoxifen treatment, *Hnf4a-DreER*;*Sox9-CreER*;*R26-Confetti2* mice were subjected to DDC-induced liver injury, and liver tissues were collected for analysis after 8--10 weeks. We observed very sparse labeling in the injured liver, and cell labeling could be categorized into three distinct clones: hepatocytes, BECs, and mixed clones that contained both hepatocytes and BECs ([Figures 6](#fig6){ref-type="fig"}A and 6B). Two or three labeled hepatocytes, such as nGFP^+^ or YFP^+^ hepatocytes, were detected ([Figures 6](#fig6){ref-type="fig"}A and 6B), indicating cell proliferation after liver injury. To determine whether some of the labeled SOX9^+^ hepatocytes generated BECs after injury, we stained the liver sections with CK19 and developed the signal in the far-red channel to avoid mixing with other fluorescence signals. In each field there was only one clone with a unique fluorescent color, such as GFP, YFP, or RFP. We found that a substantial number of clones exhibited CK19 expression, indicating that they were the BEC clones (arrowheads, [Figures 6](#fig6){ref-type="fig"}A and 6B). Fewer clones were hepatocytes in the injured liver, and these labeled hepatocytes in one clone were usually detected in a cluster (arrows, [Figures 6](#fig6){ref-type="fig"}A and 6B), indicating their proliferation after injury. Interestingly, we also detected mixed clones that contained both hepatocytes and BECs in one single-color clone ([Figures 6](#fig6){ref-type="fig"}A and 6B), suggesting that these two different cell lineages could be derived from a single SOX9^+^ hepatocyte. We next collected serial liver sections and stained them with CK19 for analysis of all the labeled cells in each clone ([Figure 6](#fig6){ref-type="fig"}C). Serially stained sections showed the clone clearly in the liver and confirmed the bipotency of a single SOX9^+^ hepatocyte during liver injury ([Figures 6](#fig6){ref-type="fig"}C, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}). Quantification of the three types of clones in *Hnf4a-DreER*;*Sox9-CreER*;*R26-Confetti2* livers after injury showed hepatocyte clones, BEC clones, and mixed clones that constituted 35.32% ± 0.82%, 55.54% ± 2.10%, and 9.13% ± 1.91% of all clones, respectively ([Figure 6](#fig6){ref-type="fig"}D). We also quantified the cell number of each clone and found that there were 4.73 ± 0.39 hepatocytes in hepatocyte clones; 6.03 ± 0.41 BECs in BEC clones; and 2.87 ± 0.20 hepatocytes and 6.78 ± 0.42 BECs in mixed clones ([Figure 6](#fig6){ref-type="fig"}E). We confirmed the bipotency of SOX9^+^ hepatocytes by clonal analysis in the BDL model ([Figure S7](#mmc1){ref-type="supplementary-material"}). Thus, clonal fate-mapping analysis of a single SOX9^+^ hepatocyte showed their uni- and bipotency during liver injury and repair ([Figure 6](#fig6){ref-type="fig"}F).Figure 6Identification of Bipotent SOX9^+^ Hepatocyte after Liver Injury(A and B) Fluorescent sections stained with BEC marker CK19 shows three distinct clones: hepatocyte clone, BEC clone, and mixed clone that contains both hepatocyte and BEC. Arrows or arrowheads indicate nGFP^+^, RFP^+^, or YFP^+^ hepatocytes or BECs, respectively. Cartoon images in (B) denote the magnified images in (A).(C) Serial sections of a bipotent clone that contains both BECs (arrowheads) and hepatocytes (arrows).(D) Quantification of the percentage of three types of clones in injured liver. A total of 246 clones were analyzed. Data are mean ± SEM; n = 5.(E) Quantification of cell number in each type of clones. A total of 246 clones were analyzed. Data are mean ± SEM; n = 5.(F) Cartoon figure showing the cell fate of three types of clones after injury.Scale bars, 100 μm.

Discussion {#sec3}
==========

Two major epithelial cell populations, BECs and hepatocytes, have recently been reported to give rise to each other under specific injury or disease conditions ([@bib4], [@bib24], [@bib26], [@bib32], [@bib37], [@bib36]). Whether a single hepatocyte is bipotent for both BECs and hepatocytes remains unknown. A recent study reported that SOX9^+^ hepatocytes exhibit a high proliferative potential depending on the condition of injury without tumorigenesis ([@bib8]). In our study, we used a dual recombinase-based lineage-tracing strategy to genetically target SOX9^+^ hepatocytes. We found that a single SOX9^+^ hepatocyte differentiated into both BECs and hepatocytes after injury, providing genetic evidence for the existence of bipotent SOX9^+^ hepatocytes as progenitor cells for liver repair and regeneration.

This work mainly utilized genetic tools to specifically label SOX9^+^ hepatocytes. The combination of Cre-loxP and Dre-rox allowed another layer of regulation in the specificity in genetic targeting. Our recent study using dual recombinases and a nested reporter (*NR1*) permitted specific labeling of SOX9^+^ BECs without contamination of SOX9^+^ hepatocytes ([@bib14]). Unlike a previous study reporting the differentiation of SOX9^+^ ductal cells to hepatocytes ([@bib9]), our fate mapping of SOX9^+^ BECs showed their ductal cell fate but not hepatocyte fate via differentiation during liver homeostasis or after injury ([@bib14]). The proposed ductal cell-specific *Sox9-CreER* used in a previous study ([@bib9]) might not be specific for ductal cells, as SOX9 is also expressed in hepatocytes ([Figures 1](#fig1){ref-type="fig"}C and 1G), although the expression level of SOX9 in hepatocytes is lower than that that of BECs. As *Sox9-CreER* labels hepatocytes in addition to BECs, the contribution of SOX9^+^ progenitors to hepatocytes ([@bib9]) could also be interpreted to indicate that SOX9^+^ hepatocytes labeled at the beginning contributed to more hepatocytes during liver regeneration after injury. Genetic lineage tracing with "duct-specific" Cre stains should be carefully examined to determine whether any hepatocyte was labeled.

With the advent of single-cell sequencing technology, more different subsets of hepatocytes ([@bib12]) or biliary epithelial cell populations ([@bib32]) could be elucidated, and their *in vivo* functions remain largely unknown. Our dual recombinase-mediated genetic systems reported here would be valuable to more precisely label a subset of liver cell populations and study their cell fate during liver homeostasis and injuries. Moreover, we recently developed a sequential intersectional genetics strategy whereby Dre-rox recombination mediates the release of Cre ([@bib22]). This strategy would also allow gene functional analysis by crossing the Dre-mediated Cre mouse strain with the available flox gene allele for *in vivo* gain- or loss-of-function studies. Moreover, dual recombination systems could be used to manipulate two distinct cell populations *in vivo* to understand their function and cell plasticity during liver injuries.

SOX9 has been previously studied as a progenitor or stem cell marker for cell expansion and fate determination ([@bib11], [@bib15], [@bib39]). During injury, SOX9 could also be activated in hepatocytes ([@bib2], [@bib13]). SOX9^+^ hepatocytes are located near ductal cells and could contribute to BECs during liver injuries ([@bib37]). These SOX9^+^ hepatocytes, compared with the remaining SOX9^--^ hepatocytes, have a propensity to contribute to BECs after injuries. Quantitatively, the contribution of SOX9^+^ hepatocytes to BECs was 10-fold more efficient than SOX9^--^ hepatocytes after BDL- or DDC-induced liver injuries. SOX9 may predispose hepatocytes to conditions that facilitate reprogramming into BECs ([@bib37]). Signaling pathways that regulate hepatocytes to BECs include Notch ([@bib6], [@bib28]), Hippo-Yap ([@bib38]), and TGFβ ([@bib26]). Whether these signaling pathways were activated in SOX9^+^ hepatocytes to modulate their bipotency after liver injury merits investigation in the future. Alternatively, the adjacent ductal cells could directly or indirectly affect and reprogram the cell fate of SOX9^+^ hepatocytes. Whether ductal cells influence the cell fate of hepatocytes through paracrine signaling remains unknown, and niche signaling has now been reported to influence the function of cells rather than the hard-wired property of stem cells ([@bib3]). It is therefore of interest whether these SOX9^+^ hepatocytes, relocated away from the portal region, could maintain the robust ability to differentiate into BECs. Elucidation of the regulatory mechanism of SOX9^+^ hepatocyte progenitors may provide information for amplifying the bipotent progenitor population for potential applications in liver repair and regeneration. As SOX9^+^ hepatocytes are unique in their ability to differentiate into BECs and expand hepatocytes, they could be a potentially important drug target for treating liver diseases in the future.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

All mouse studies were carried out strictly according to the guidelines of the Institutional Animal Care and Use Committee at the Institute of Biochemistry and Cell Biology and the Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. *Hnf4a-DreER* was generated by CRISPR/Cas9 through homologous recombination. A complementary cDNA encoding IRES-DreER^T2^ was inserted in-frame with the translation codon of the *Hnf4a* gene. The chimeric mice positive for targeted ESCs were germline transferred to F1 generation and bred on a C57BL/6 × ICR background. The *Sox9-CreER*^*T2*^ line was generated by the National Institute for Biological Sciences, Beijing, China. *R26-Ai66* (*Rosa26-rox-Stop-rox-loxP-Stop-loxP-tdTomato*) was generated as reported previously ([@bib17], [@bib40]). The *Rosa26-Rox-Stop-Rox-tdTomato* (*R26-RSR-RFP*) mouse line was generated by crossing *ACTB-Cre* with *R26-Ai66* to excise the second loxP-flanked Stop cassette, and *ACTB-Cre* was not passaged to the subsequent mouse breeding. *R26-RSR-RFP* was responsive to Dre but not Cre recombinase. The *Rosa26-rox-Stop-rox-Confetti* (*R26-Confetti2*) was generated by targeting CAG-rox-Stop-rox-Confetti cassette into the Rosa26 gene locus by homologous recombination ([Figure 5](#fig5){ref-type="fig"}A). All experimental mice were maintained on a C57BL6/ICR mixed background. Tamoxifen (Sigma, T5648) was dissolved in corn oil (20 mg/mL) and administered by gavage at the indicated time points. We treated *R26-RFP* and *R26-Confetti2* mice with 0.4 mg of tamoxifen per gram of mouse body weight (mg/g) and 0.15 mg/g tamoxifen, respectively.

Genomic PCR {#sec4.2}
-----------

Genomic DNA was prepared from mouse tails according to the standard protocols described previously ([@bib35]). All mice were genotyped with specific primers that distinguish knockin allele from wild-type allele. Information on the primers can be found in [Supplemental Information](#app3){ref-type="sec"}.

Injury Model {#sec4.3}
------------

For the CCl~4~-induced chronic injury model, CCl~4~ was dissolved at 1:3 in corn oil and injected intraperitoneally at a dose of 4 μL/g body weight every 3 days, repeated 10 times. Partial hepatectomy (PHx) was generated by removing two-thirds of the liver to induce the injury ([@bib35]). The BDL injury model was prepared according to established protocols described previously ([@bib23]). For the DDC-induced chronic injury model, mice received mouse diet (Harlan Teklad, 5015) containing 0.1% DDC (Sigma-Aldrich).

Whole-Mount Fluorescence Microscopy {#sec4.4}
-----------------------------------

Collected mouse liver was washed in PBS and placed on agar for the whole-mount bright-field and fluorescence imaging using a Zeiss stereoscope (AxioZoom V16). To determine magnification of specific regions, we used the automated z-stack images acquired by the stereoscope (Zeiss AxioZoom V16).

Immunostaining {#sec4.5}
--------------

Immunostaining was performed according to the standard protocols described previously ([@bib33]). The following antibodies were used: RFP (Rockland, 600-401-379, 1:200), HNF4a (Santa Cruz Biotechnology, sc-6556, 1:100), cytokeratin 19 (CK19, Developmental Studies Hybridoma Bank, TROMA-III, 1:100), VE-cadherin (R&D Systems, AF1002, 1:100), desmin (R&D, AF3844, 1:100), PDGFRα (R&D, AF1062, 1:100), E-cadherin (Cell Signaling Technology, 3195, 1:100), EpCAM (Abcam, ab92383, 1:100), αSMA (Sigma, F3777, 1:100), and Ki67 (Thermo Scientific, RM-9106-S0, 1:100). Signals were developed with Alexa fluorescence antibodies (Invitrogen), and nuclei were counterstained with 4′,6-diamidino-2-phenylindole (Vector Laboratories). For clonal analysis, CK19 was stained on the liver sections in the far-red channel. In total 246 clones were analyzed: 820 cholangiocytes in cholangiocyte clones; 412 hepatocytes in hepatocyte clones; 156 cholangiocytes; and 66 hepatocytes in mixed clones. There was bleed-through of fluorescence for YFP and GFP because the YFP signal could also be detected in the GFP channel. In addition, our GFP is nGFP (nuclear), so the pure GFP signal should be in the nucleus while the bleed-through signal in the GFP channel from YFP should not be a nuclear signal. Immunostaining images were acquired by an Olympus fluorescence microscope (BX53), a Zeiss stereomicroscope (AxioZoom V16), a Zeiss confocal laser scanning microscope (LSM510), and an Olympus confocal microscope (FV1200).

Sirius Red Staining {#sec4.6}
-------------------

Sirius red staining was used to assess fibrotic tissue in chronic injury models, and was performed according to the standard protocols described previously ([@bib35]).

Statistics {#sec4.7}
----------

All data were collected from at least five independent experiments as indicated. Data for two groups were analyzed by a two-sided unpaired Student\'s t test, whereas comparison between more than two groups was performed using an analysis of variance followed by Tukey\'s multiple comparison tests. Significance was accepted when p \< 0.05. All data are presented as mean values ± SEM.
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